124 related articles for article (PubMed ID: 17351254)
1. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.
Bergqvist J; Ohd JF; Smeds J; Klaar S; Isola J; Nordgren H; Elmberger GP; Hellborg H; Bjohle J; Borg AL; Skoog L; Bergh J
Ann Oncol; 2007 May; 18(5):845-50. PubMed ID: 17351254
[TBL] [Abstract][Full Text] [Related]
2. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
3. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
[TBL] [Abstract][Full Text] [Related]
4. Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.
Schlemmer BO; Sorensen BS; Overgaard J; Olsen KE; Gjerdrum LM; Nexo E
Scand J Clin Lab Invest; 2004; 64(5):511-22. PubMed ID: 15276916
[TBL] [Abstract][Full Text] [Related]
5. Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Wixom CR; Albers EA; Weidner N
Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):248-51. PubMed ID: 15551739
[TBL] [Abstract][Full Text] [Related]
6. An alternative and sensitive method based on LCM and Q-PCR for HER2 testing in breast cancer.
Fetica B; Balacescu O; Balacescu L; Rus M; Berindan-Neagoe I
Cancer Biomark; 2014; 14(2-3):129-35. PubMed ID: 24878813
[TBL] [Abstract][Full Text] [Related]
7. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
[TBL] [Abstract][Full Text] [Related]
8. [Comparision of HER2/neu oncogene detected by chromogenic in-situ hybridization and immunohistochemistry in breast cancer].
Zhang GH; Shi DR; Liang XM; Hou JH; Kang SY; Zhu WD; Li XB; Shao Y; Chen LR; Zhou Y
Zhonghua Bing Li Xue Za Zhi; 2006 Oct; 35(10):580-3. PubMed ID: 17134562
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HER2 Gene Status in Breast Cancer Samples with Indeterminate Fluorescence in Situ Hybridization by Quantitative Real-Time PCR.
Koudelakova V; Berkovcova J; Trojanec R; Vrbkova J; Radova L; Ehrmann J; Kolar Z; Melichar B; Hajduch M
J Mol Diagn; 2015 Jul; 17(4):446-55. PubMed ID: 25956448
[TBL] [Abstract][Full Text] [Related]
10. Detection of HER2 status in breast cancer: comparison of current methods with MLPA and real-time RT-PCR.
Pazhoomand R; Keyhani E; Banan M; Najmabadi H; Khodadadi F; Iraniparast A; Feiz F; Majidzadeh K; Bahman I; Moghadam FA; Sobhani AM; Muhammadnejad A; Abedini SS; Behjati F
Asian Pac J Cancer Prev; 2013; 14(12):7621-8. PubMed ID: 24460343
[TBL] [Abstract][Full Text] [Related]
11. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
[TBL] [Abstract][Full Text] [Related]
12. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study.
Vincent-Salomon A; MacGrogan G; Couturier J; Arnould L; Denoux Y; Fiche M; Jacquemier J; Mathieu MC; Penault-Llorca F; Rigaud C; Roger P; Treilleux I; Vilain MO; Mathoulin-Pélissier S; Le Doussal V
Histopathology; 2003 Apr; 42(4):337-47. PubMed ID: 12653945
[TBL] [Abstract][Full Text] [Related]
13. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
[TBL] [Abstract][Full Text] [Related]
14. Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.
Zoppoli G; Garuti A; Cirmena G; di Cantogno LV; Botta C; Gallo M; Ferraioli D; Carminati E; Baccini P; Curto M; Fregatti P; Isnaldi E; Lia M; Murialdo R; Friedman D; Sapino A; Ballestrero A
J Transl Med; 2017 May; 15(1):91. PubMed ID: 28460632
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of a novel RT-qPCR based test for the quantification of HER2 gene expression in breast cancer.
El Hadi H; Abdellaoui-Maane I; Kottwitz D; El Amrani M; Bouchoutrouch N; Qmichou Z; Karkouri M; ElAttar H; Errihani H; Fernandez PL; Bakri Y; Sefrioui H; Moumen A
Gene; 2017 Mar; 605():114-122. PubMed ID: 28039034
[TBL] [Abstract][Full Text] [Related]
16. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
Barberis M; Pellegrini C; Cannone M; Arizzi C; Coggi G; Bosari S
Am J Clin Pathol; 2008 Apr; 129(4):563-70. PubMed ID: 18343783
[TBL] [Abstract][Full Text] [Related]
17. A comparative assessment of HER2 status in operable breast cancer by real-time RT-PCR and by immunohistochemistry.
Potemski P; Płuciennik E; Bednarek AK; Kusińska R; Pasz-Walczak G; Jesionek-Kupnicka D; Watala C; Kordek R
Med Sci Monit; 2006 Dec; 12(12):MT57-61. PubMed ID: 17136015
[TBL] [Abstract][Full Text] [Related]
18. HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies.
Chang E; Lee A; Lee E; Lee H; Shin O; Oh S; Kang C
J Korean Med Sci; 2004 Jun; 19(3):390-6. PubMed ID: 15201505
[TBL] [Abstract][Full Text] [Related]
19. Chromogenic In Situ Hybridisation Test for Breast Cancer Patients with Equivocal IHC Results--a Study from Iran.
Mehrazma M; Kalantari E; Rezvani H; Bahar B; Basi A; Razavi SM; Rakhshani N
Asian Pac J Cancer Prev; 2015; 16(17):7695-700. PubMed ID: 26625783
[TBL] [Abstract][Full Text] [Related]
20. Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assessment in breast cancer.
Hauser-Kronberger C; Dandachi N
J Mol Histol; 2004 Aug; 35(6):647-53. PubMed ID: 15614619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
